Roivant Sciences Ltd. → Arbutus Biopharma Corp ABUS

Item 4 is hereby amended by adding the following to the end thereof: On February 21, 2025, Roivant's Chief Executive Officer, Matthew Gline, met with the Board of Directors of the Issuer and requested that each of the members of the Board of Directors resign from their position as a director of the Issuer. As announced by the Issuer, each member of the Issuer's Board of Directors agreed to the request and resigned on February 24, 2025. In conjunction with their resignations, the Board of Directors agreed to (i) reduce the number of directors from seven to five; and (ii) replace the Issuer's Board of Directors with five individuals - Lindsay Androski, Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija - to serve until the 2025 Annual General Meeting of Shareholders or until their respective successors are duly elected or appointed. In addition, as disclosed by the Issuer, the Board of Directors has appointed Ms. Androski to serve as President and Chief Executive Officer of the Issuer. Ms. Androski, along with Mr. Gline and Mr. Bishop, are employees of Roivant Sciences, Inc., a wholly-owned subsidiary of Roivant.